Rate My Professor Mehbuba Hossain

Hossain earned her PhD in Cancer Genetics and Epigenetics from the University of Otago in 2023, with a thesis titled 'Investigation of potential genomic biomarkers to predict immunotherapy response in melanoma,' supervised by Professors Michael R. Eccles and Aniruddha Chatterjee. She previously obtained a Master of Biomedical Science from Monash University, Australia. During her PhD from 2019 to 2023 in the Chatterjee Laboratory with co-supervision from the Eccles lab, and continuing as a postdoctoral fellow, her work culminated in high-impact publications, including 'Pre-treatment DNA methylome and transcriptome profiles correlate with melanoma response to anti-PD1 immunotherapy' (Cancer Letters, 2025), 'Phenotype Switching and the Melanoma Microenvironment: Impact on Immunotherapy and Drug Resistance' (International Journal of Molecular Sciences, 2023, cited 92 times), 'Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma' (IJMS, 2024), and 'Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma' (IJMS, 2024). With 316 citations on Google Scholar, her contributions advance personalized medicine and precise melanoma treatments. Awards include the NZ Institute for Cancer Research Trust Postdoctoral Fellowship, Otago Doctoral Scholarship, Monash University Merit Scholarship, and grants from the Maurice Wilkins Centre and Maurice and Phyllis Paykel Trust.